ABSTRACT

Background
There is good evidence for the benefits of short-term Cognitive Stimulation Therapy for dementia but little is known about possible long-term effects.
Aims
To evaluate the effectiveness of maintenance Cognitive Stimulation Therapy for people with dementia in a single-blind, pragmatic randomised controlled trial including a sub-study with participants taking acetylcholinesterase inhibitors (ACHEIs).
Method
The participants were 236 people with dementia from nine care homes and nine community services. Prior to randomisation all participants received the seven-week 14-session CST programme. The intervention group received the weekly Maintenance CST group programme for 24 weeks. The control group received usual care. Primary outcomes were cognition and quality of life.
Results
For the intervention group at the six-month primary end point there were significant benefits for self-rated quality of life (QoL-AD p=0.03). At three months there were improvements for proxy-rated quality of life (QoL-AD p=0.01: DEMQOL p=0.03), and activities of daily living (p=0.04). The intervention sub-group taking ACHEIs showed cognitive benefits (on the MMSE) at three (p=0.03) and six months(p=0.03) .
Conclusions
Continuing CST improves quality of life; and improves cognition for those taking ACHEIs.
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INTRODUCTION
There is good evidence for the benefits of cognitive stimulation for people with dementia.1 A recent Cochrane review showed that cognitive stimulation improved both cognition and quality of life.2 The review concluded the benefits of cognitive stimulation enhanced those of medication, and that it was effective whether or not acetylcholinesterase inhibitors (ACHEIs) were prescribed.2 The 2011 World Alzheimer report concluded "there is strong evidence to support cognitive stimulation programmes and these interventions should therefore be routinely offered". 3 Cognitive stimulation is a psychological intervention for dementia that targets cognitive and social functioning and is designed to enhance general cognitive abilities. Cognitive Stimulation Therapy (CST) is a well-defined evidence-based version of cognitive stimulation which is standardised, including 2 training manuals and a DVD. 4 CST was developed following review of a related approach known as Reality Orientation (RO)5 and evaluated CST in a pilot trial,6 followed by a full trial,4 and developed a manual7 and a training DVD. CST is now used widely across the UK and in several other countries. A pilot study of maintenance CST which continued for an extra 16 weekly sessions beyond the standard seven-week (14-session) CST programme 8 found a significant improvement in cognitive function compared with CST alone. The Cochrane Review found no link between duration or frequency of the programme and degree of improvement. 2 Some studies have continued cognitive stimulation for six months or more, 9,10 but there is little evidence about how far potential benefits may continue after sessions end. The Cochrane Review suggested that after the sessions finished the effects on cognition were evident for at most three months; 2 and another study found no continuing effects at ten months.11 This trial aimed to evaluate the effectiveness of Maintenance CST in improving cognition and quality of life in people with dementia who have completed the standard CST programme. Hence the intervention group would continue with maintenance CST whereas the control group would have standard CST only followed by treatment as usual.12 In addition, a sub-study focused on the effects of maintenance CST on people with dementia taking ACHEIs.
METHODS
Study Design
This was a single-blind, multi-centre, pragmatic randomised controlled trial comparing (1) Maintenance CST groups after completing standard CST vs (2) standard CST only followed by treatment as usual. 13 There was no modification in design or eligibility criteria from the study protocol12 available at http://www.trialsjournal.com/content/pdf/1745-6215-11-46.pdf. The clinical trial registration number is ISRCTN26286067.
Participants
Potential centres were screened for eligibility to determine whether there were sufficient numbers of potential participants with dementia, using the inclusion criteria flow chart. Participants all met the DSM-IV criteria for dementia14 using the diagnostic algorithm and most had either Alzheimers or vascular dementia. All had mild (45%) to moderate dementia (55%) on the Clinical Dementia Rating scale;15 could communicate, hear and see well enough to participate in the group; had no major physical illness or disability, or diagnosed learning disability. All trial participants completed seven weeks of CST4 comprising fourteen twice-weekly 45-minute sessions according to the CST manual.7
Approximately half of the participants from nine care homes, and half from nine community services within London, Essex and Bedfordshire. The community centres included four voluntary sector specialist dementia day centres, and five centres based in local Community Mental Health Teams for older people. The nine care homes included; five provided by Social Services, one by the private sector, and three by a voluntary organisation. Of 21 centres approached, one refused and two had too few eligible participants. Maintenance CST session has a specific theme or activity (e.g. current affairs; my life; word games) within a consistent structure including orientation-based activity, refreshments and a group song. Each group had two facilitators, one from the research team and one staff member from the participating centre (i.e. care home or community service). All facilitators had at least one year of experience in dementia care, and had attended the one-day CST training course.
Outcome measures
Participants were interviewed at baseline, before randomisation, at three months (intermediate end point) and after six months (primary end point).
Researchers collected the proxy ratings of the quality of life measures, the NPI and the ADCS-ADL in structured interviews: with staff for participants in care homes; and with family carers for those in the community.
Primary outcomes
(1) Alzheimer's Disease Assessment Scale -Cognition Subscale (ADAS-Cog). This is the standard cognitive test used in clinical trials for dementia. 19 This comprises 11 tasks measuring memory, language, praxis, attention and other cognitive abilities. Lower scores reflect better cognition. 
Sample size
Based on the Cochrane Review we estimated effect size for Maintenance CST of 0.39 on the ADAS-Cog with power of 80% when using 5% significance level and estimating attrition at 15% between baseline and six months. This required a sample size of 230 participants randomised at baseline and an estimated 195 at follow up. With an estimated 60 participants with Alzheimer's disease and taking ACHEIs, this provided sufficient numbers for the maintenance CST/ACHEIs sub-study to estimate effect size and the feasibility of a full scale trial.
Randomisation
All participants completed the initial CST programme13 and were then allocated at random between (1) the intervention group receiving weekly Maintenance CST for 24 weeks or (2) the control group receiving treatment as usual (TAU). The NWORTH Clinical Trials Unit remotely randomised participants in equal proportions between groups after stratifying for: centre (community service or care home), whether ACHEI was prescribed, and previous CST group. The random allocation sequence was computergenerated and in the ratio of 1:1. NWORTH emailed the individual allocation to the site researcher delivering the intervention and stored the allocation list under a secure password, which was not available to any study site staff. The scheduled treatment sessions, session records and participant records were saved at the site, strictly separated, and distant from the coordinating study centre. Once the trial was completed in each centre, records were transferred to the coordinating study centre and stored by the study centre administrator who was not involved in the assessment process or data analysis. This was in order to avoid contamination. The nature of the intervention prevented us from blinding participants to their allocated group. However blind researchers conducted initial and subsequent interviews, generally in care homes or participants' own homes. The statistician conducting the data analysis was also blind to group assignment.
Statistical analysis
We used the MACRO system to manage the data. Data was entered manually and audited internally for typing errors by hand, in order to ensure a low error rate. Data was transferred to SPSS and audited externally by NWORTH with hard copies of assessments. These audits entailed cross checking a random 10% sample of the electronic data with the paper records to ensure accurate entry. Both random and systematic data entry errors were identified and corrected. As the audits were carried out in parallel with data entry systematic errors could be corrected at an early stage. The dataset is available from the corresponding author at m.orrell@ucl.ac.uk. Participants' consent was obtained, but the data presented are anonymised and risk of identification is low. For participants with some follow-up data, we imputed individual data missing within a scale according to the validated rules for that scale; and missing total scores by multiple regression on variables including allocated group, age, gender, ethnicity, marital status, whether prescribed an ACHEI, staff or family caregiver, centre type and individual centre (using random effects). We adopted a forward stepwise model, and used baseline scores to help predict scores at three months, then both of these to predict scores at six months, since no participant missing at three months returned at six months.
Primary analyses by treatment allocated used analysis of covariance to adjust all imputed data for baseline differences in age, gender, ethnicity, marital status, prescription of ACHEIs, proportion of family caregivers, individual centre (using random effects) and baseline score on the variable under analysis. We then estimated the effect of treatment from the resulting model.
The maintenance CST/ ACHEIs trial platform followed the same methodology as for the primary analysis and used the interaction term between ACHEIs and the treatment group to identify any effect between the two factors for the outcome measures.
Results
The recruitment period took place between January 2009 and September 2010. The final 24-week follow up was completed in May 2011. Of 272 people with dementia that started the CST groups and were considered for the trial, 36 were withdrawn (Table 1) . We followed up 218 participants (92% of 236; 96% of those still alive) at 3 months and 199 (84% of 236; 89% of those still alive) at 6 months. The CONSORT flowchart (Figure 1 ) records the reasons for subsequent withdrawals. The withdrawal rate was similar in both arms of the trial. Of the 236 participants, 123 were allocated to the Maintenance CST group and 113 to usual care (TAU). The groups were well matched at baseline and randomisation avoided imbalances ( Table 2 ). The mean age was 83 years and most participants were white females. On average participants allocated to the Maintenance CST groups attended 18 of the 24 available sessions.
Outcomes
At the six-month primary end-point (Table 3) , the Maintenance CST group had higher scores than the TAU group on self-rated QoL-AD (first primary outcome) which reached statistical significance with mean difference 1.78 (95% CI 0.00 to 3.60; p=0.03). There were no significant differences on ADAS-Cog (second primary outcome). There were no significant differences in secondary outcomes at six months. There were two types of centre studied, care homes and community services. There were significant differences among the centres over and above that explained by centre type.
At three months there were no significant differences on either primary outcome. For secondary outcomes, participants randomised to the intervention group had significantly better scores than controls on proxy ratings of quality of life (QoL-AD and DEMQOL) and daily activities. The mean difference on the proxy QoL-AD was 1.53 (95% CI 0.35 to 2.71; p=0.01); and for the proxy DEMQOL it was 3.24 (95% CI 0.24 to 6.24; p=0.03). The difference on the ADCS-ADL was 2.64 (95% CI 0.04 to 5.24; p=0.04).
Quality of maintenance CST programme provision
To estimate the quality of the maintenance CST provision after each session the researchers made ratings on a range of factors related to the successful running of the groups: manager's attitude (0-2), centre atmosphere (0-2), co facilitators input (0-2), group atmosphere (0-2), and average number of sessions attended by participants (0 = less than 12, 1 = 13-20, 2 = 21-24) with higher scores indicating better quality. Centres were divided into low quality (score 0-5) and high quality (score 6-10). Eight out of 9 community centres scored as high quality compared to only 6 out of 9 care homes. The quality indicator was incorporated into the model of analysis with primary outcome results, with baseline score, centre type, age and allocation as a fixed effect and within a random effect of centre nested within the interaction of quality and type. The analysis showed that both centre type and quality of CST provision were not significant in the model using either QoL-AD or ADAS-Cog.
There were differences among the centres that could not be explained by amount of sessions attended or quality of CST provision.
Maintenance CST/ ACHEI trial platform results
There were no significant results in relation to primary outcomes. Table 4 shows the observed means and SD at baseline. The means and SDs presented at follow-ups 1 and 2 are adjusted for the factors and covariates in the fitted model including the treatment group by ACHEIs interaction term.
The follow-up means are standardised to a common baseline mean value.
The significance levels quoted below are for the interaction term. Only for MMSE at both three and six months follow-up were significant interactions found. The results show that starting from a mean baseline MMSE of 17. Between baseline and second follow up 92% had no changes to their to ACHEI status with three participants stopping (1 TAU/2 MCST) and 11 starting (4 TAU/7MCST) medication.
There were no differences between the groups (intervention and control) in the number of reported adverse events or severity. In the intervention group there were five deaths and four withdrawals due to health issues. In the usual care group there were six deaths and five withdrawals due to health issues.
All events were judged as unrelated to trial treatment or assessment contacts by the study trial coordinator and Principal Investigator.
DISCUSSION
Main findings
Cognitive stimulation for people with dementia is recognised as being effective 2,13 and cost effective 26 , and CST in particular improves both cognition and quality of life. 4, 13 This trial finds that after the initial CST programme, a further 24-week course of weekly Maintenance CST improves quality of life at six-month follow up but confers no additional benefit to cognition. At six months it was only participants who reported improved quality of life (a small standardised difference of 0.35), whereas at three months only the proxy respondents (carers/care staff) noted the improvement (a small standardised difference of 0.30). Participants in the intervention group also improved in their activities of daily living at three months (a very small standardised difference of 0.15). There were no significant differences in other outcomes at either three or six months. The sub-study results suggest that people on ACHEI medication may benefit cognitively from maintenance CST suggesting a synergistic effect. This is in line with other studies combining ACHEIs and cognitive stimulation4,8,13, and the Cochrane review2 which found that the effect of cognitive stimulation on cognition is over and above the effects of medication alone. The relevance in terms of clinically significant change is less clear. A mean decrease of 1 point versus 4 points on the MMSE scale may make a big difference for some people with dementia. The difference might translate into economic benefits since a difference of 1 point in the MMSE score may be associated with substantial reductions in the costs of caring for people with dementia27. The CST programme prior to baseline resulted in mean improvements of 4.4 points on the ADAS-Cog and 2.7 points on the MMSE 13 . Since dementia is associated with progressive cognitive decline there may have been limited potential for further cognitive improvement with the maintenance programme. This means that at six-month follow-up both groups were likely to have declined from the baseline taken after the CST groups finished, and so significant differences in cognition were only likely to be found if the usual care (CST only) group had declined more than the maintenance group.
Strengths and limitations
As participants came from nine care homes and nine community services across London, Essex and Bedfordshire, this pragmatic trial is likely to be generalisable in many respects. However, since participants were almost all white it is hard to say how far CST is useful for other ethnic or cultural groups.
Nevertheless, we have recently adapted the CST programme for a south Asian population and successfully run a local group in Hindi and Gujarati.
Although we took great care to blind our researchers to allocated treatment, we could not blind those care staff and family carers who provided proxy ratings for four measures (ADCS-ADL, NPI, QoL-AD and DEMQOL) and this means there is a risk of detection bias. Notably these measures provided three of the four significant findings. Compared to the original CST study this trial had more diversity in dementia severity due to a much higher proportion recruited from the community (50% vs 15%). This resulted in the standard deviations of the cognitive measures being much higher than in the original trial of CST 4. A larger trial might find significant differences in cognition after weekly Maintenance CST. However, it may be that more frequent groups would be more efficacious. This was the first rigorous trial of Maintenance CST. The results are encouraging but not conclusive and suggest that further trials are needed and it will be important for other groups to evaluate Maintenance CST. 28 Future research could look in more depth at the optimum frequency and duration of CST groups, for example to continue to provide CST twice a week (rather than once weekly) for a six month period. Another option would be to repeat the standard 7 week CST programme for example after a 4 month break. However, this option could be disruptive to the groups, and would not mirror the standard approach used in drug interventions which are given without interruption rather than as a short course.
Clinical implications
In the previous stage of this study before and after CST (prior to randomisation) we found that both cognition and quality of life significantly improved, including for those people on ACHEIs.13 However following Maintenance CST at six-month follow-up we found no significant differences in cognition. There were no differences on the ADAS-Cog although the MMSE showed a 0.85 points advantage for the Maintenance CST group. This does not suggest that Maintenance CST has substantial effects on cognition over and above the original benefits of the initial CST programme.2 MMSE scores in mild to moderate dementia generally decrease by 2 to 4 points per year,29.
Before the initial CST programme 13 group. This suggests that CST may continue to have some degree of protective effect on cognition over and above the effects of medication. Other studies using usual care control groups have also found that a programme of cognitive stimulation sessions over a longer time period can be effective in reducing cognitive decline in dementia. 30, 31 In chronic conditions quality of life may be more important for older adults than disease-specific outcomes and it is a key outcome that interventions for dementia should target. Benefits to cognition alone may not be sufficient to justify an extensive programme of intervention unless they are accompanied by other benefits such as quality of life 32 . Two recent systematic reviews highlighted that there are few well-designed studies on the effectiveness of either pharmacological 33 or psychosocial 34 interventions on quality of life. Like other follow up studies we found that individual changes in quality of life were apparent for nearly three-quarters of our sample 35, 36, 37 . In contrast to the Cochrane review of cognitive stimulation our study found that activities of daily living improved at three-month follow-up. However, previous research 35 suggests that there may be a correlation between proxy rated quality of life and activities of daily living. It might be that the effects of the intervention on proxy rated quality of life was linked with the effects on activities of daily living.
At six-month follow-up these proxy rated domains showed no difference.
However, for the person with dementia a temporary improvement in quality of life, cognition, or activities of daily living may all be considered worthwhile
Future research
As this was the first rigorous trial of Maintenance CST, we encourage others to implement and evaluate this novel extension in other populations in other contexts with other staff. In our research programme we have three further cognitive stimulation therapy studies 28 Firstly, we are undertaking a pragmatic 
